Patents by Inventor Sang-Ho Ma
Sang-Ho Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220402909Abstract: Provided are a compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same and a use thereof, where the compound having a 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof has an inhibitory activity against glucosylceramide synthase (GCS), and therefore can be usefully applied for preventing or treating various diseases associated with GCS, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Parkinson's disease, etc.Type: ApplicationFiled: November 12, 2020Publication date: December 22, 2022Applicants: YUHAN CORPORATION, GREEN CROSS CORPORATIONInventors: Dong-Hoon KIM, Jae-Eun JOO, Eui-Chul LEE, Tae-Dong HAN, Seung-Yub SHIN, Sool-Ki KWON, Young-Gyu KONG, Sang-Ho MA, Ick-Hwan SON
-
Patent number: 10851985Abstract: An LED module that includes a light source unit which includes one or more LEDs mounted on one surface of a circuit board, a heat sink which includes a base substrate configured to support the light source unit and radiate heat generated from the light source unit and an insulating heat radiation coating layer applied on an outer surface of the base substrate, a protective cover which includes a convex portion formed in a region corresponding to the LED and is coupled to one surface of the heat sink to protect the light source unit from an external environment, an air flow space formed between the light source unit and the protective cover and provides a space through which air can flows, and one or more air vents which perform a function as a passage through which the air is moved to the outside from the air flow space and balance internal pressure of the air flow space with pressure of outside air.Type: GrantFiled: April 11, 2018Date of Patent: December 1, 2020Assignee: Amosense Co., Ltd.Inventors: Gyu-Weon Shin, Sang-Ho Ma
-
Publication number: 20200124267Abstract: An LED module that includes a light source unit which includes one or more LEDs mounted on one surface of a circuit board, a heat sink which includes a base substrate configured to support the light source unit and radiate heat generated from the light source unit and an insulating heat radiation coating layer applied on an outer surface of the base substrate, a protective cover which includes a convex portion formed in a region corresponding to the LED and is coupled to one surface of the heat sink to protect the light source unit from an external environment, an air flow space formed between the light source unit and the protective cover and provides a space through which air can flows, and one or more air vents which perform a function as a passage through which the air is moved to the outside from the air flow space and balance internal pressure of the air flow space with pressure of outside air.Type: ApplicationFiled: April 11, 2018Publication date: April 23, 2020Applicant: AMOSENSE CO.,LTDInventors: Gyu-Weon SHIN, Sang-Ho MA
-
Pyrazole derivatives as TNIK, IKK? and TBK1 inhibitor and pharmaceutical composition comprising same
Patent number: 10294207Abstract: Provided is pyrazole derivatives as a TNIK (Traf2- and NCK-interacting kinase), IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits TNIK, IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.Type: GrantFiled: March 29, 2016Date of Patent: May 21, 2019Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kisoo Park, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Ickhwan Son, Sang-ho Ma, Kwang-Seop Song, Min Ju Kim, So Ok Park, Man-Young Cha, Mi-Soon Kim, Sang Mi Kang, Dong Hyuk Jang, Jangwon Hong -
Patent number: 10239873Abstract: Provided are 7-azaindole or 4,7-diazaindole derivatives as an IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor. The 7-azaindole or 4,7-diazaindole derivative effectively inhibits IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.Type: GrantFiled: March 24, 2016Date of Patent: March 26, 2019Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kwang-Seop Song, Hee Jeong Seo, Sang-ho Ma, Eun-Jung Park, Younggyu Kong, So Ok Park, Kisoo Park, Ickhwan Son, Min Ju Kim, Man-Young Cha, Mi-Soon Kim, Sang Mi Kang, Dong Hyuk Jang, Jangwon Hong
-
Patent number: 9856216Abstract: Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.Type: GrantFiled: April 21, 2016Date of Patent: January 2, 2018Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Eun-Jung Park, Hee Jeong Seo, Younggyu Kong, Ickhwan Son, Sang-ho Ma, Man-Young Cha, Mi-Soon Kim, Kisoo Park
-
Publication number: 20160311772Abstract: Provided is a compound of formula (I) as a TNIK (Traf2- and NCK-interacting kinase), IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the compound according to the present invention effectively inhibits TNIK, IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.Type: ApplicationFiled: April 21, 2016Publication date: October 27, 2016Applicant: GREEN CROSS CORPORATIONInventors: Soongyu CHOI, Eun-Jung PARK, Hee Jeong SEO, Younggyu KONG, Ickhwan SON, Sang-ho MA, Man-Young CHA, Mi-Soon KIM, Kisoo PARK
-
Publication number: 20160297815Abstract: Provided are 7-azaindole or 4,7-diazaindole derivatives as an IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor. The 7-azaindole or 4,7-diazaindole derivative effectively inhibits IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.Type: ApplicationFiled: March 24, 2016Publication date: October 13, 2016Applicant: GREEN CROSS CORPORATIONInventors: Soongyu CHOI, Kwang-Seop SONG, Hee Jeong SEO, Sang-ho MA, Eun-Jung PARK, Younggyu KONG, So Ok PARK, Kisoo PARK, Ickhwan SON, Min Ju KIM, Man-Young CHA, Mi-Soon KIM, Sang Mi KANG, Dong Hyuk JANG, Jangwon HONG
-
PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
Publication number: 20160289196Abstract: Provided is pyrazole derivatives as a TNIK (Traf2- and NCK-interacting kinase), IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits TNIK, IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.Type: ApplicationFiled: March 29, 2016Publication date: October 6, 2016Applicant: GREEN CROSS CORPORATIONInventors: Soongyu CHOI, Kisoo PARK, Hee Jeong SEO, Eun-Jung PARK, Younggyu KONG, Ickhwan SON, Sang-ho MA, Kwang-Seop SONG, Min Ju KIM, So Ok PARK, Man-Young CHA, Mi-Soon KIM, Sang Mi KANG, Dong Hyuk JANG, Jangwon HONG -
Patent number: 8940739Abstract: This invention relates to novel compounds of reverse-turn mimetics, having pyrazino-triazinone as a basic framework, and a method of preparing the same, and the use thereof to treat diseases such as cancer, in particular, acute myeloid leukemia.Type: GrantFiled: October 14, 2011Date of Patent: January 27, 2015Assignee: JW Pharmaceutical CorporationInventors: Jae-Uk Chung, Mi-Jung Kim, Yong-Sil Lee, Sang-Ho Ma, Young-Seok Cho, Sang-Hak Lee, Young-Jun Na, Myoung-Joo Kang, Woul-Seong Park
-
Publication number: 20130196972Abstract: This invention relates to novel compounds of reverse-turn mimetics, having pyrazino-triazinone as a basic framework, and a method of preparing the same, and the use thereof to treat diseases such as cancer, in particular, acute myeloid leukemia.Type: ApplicationFiled: October 14, 2011Publication date: August 1, 2013Applicant: JW PHARMACEUTICAL CORPORATIONInventors: Jae-Uk Chung, Mi-Jung Kim, Yong-Sil Lee, Sang-Ho Ma, Young-Seok Cho, Sang-Hak Lee, Young-Jun Na, Myoung-Joo Kang, Woul-Seong Park
-
Publication number: 20100267672Abstract: Disclosed are novel reverse turn mimetics based on the framework of pyrazino-triazinone, and the use thereof in the treatment of cancers, particularly, acute myeloid leukemia. A method is also provided for manufacturing the reverse turn mimetics on a mass scale.Type: ApplicationFiled: April 14, 2010Publication date: October 21, 2010Applicant: Choongwae Pharma CorporationInventors: Kyung-Yun Jung, Jae Uk Chung, Min-Wook Jeong, Hee-Kyung Jung, Hyun-Ju La, Sang-Ho Ma, Yong-Sil Lee